Compare Fubotv Inc (FUBO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Zimmer Biomet Holdings Inc — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 16.6× Fubotv Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FUBO | ZBH | |
|---|---|---|
Market Cap | $1.02B | $16.95B |
Volume | 978,631 | 2,505,240 |
Sector | Media | Health |
52-Week High | $48.96 | $103.98 |
52-Week Low | $8.09 | $79.58 |
Typical Hold Time | 35 Days | 89 Days |
Enterprise Value | $1.19B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% with bearish technical signals but attractive valuation metrics including P/E of 2.43 and P/S of 0.19. The company shows improving financials with revenue growth to $1.62B in 2024 and projected profitability in 2025. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a turnaround opportunity with deep valuation discounts and projected EBITDA growth, though execution risks remain high. The stock offers significant upside to analyst consensus target of $63.38 but faces challenges from persistent cash burn and competitive streaming landscape. Investors should weigh the potential for operational improvements against ongoing financial volatility.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
